GlaxoSmithKline to seek EMA approval for 2015 malaria vaccine launch

GlaxoSmithKline's ($GSK) experimental malaria vaccine may not have delivered results as strong as the company hoped. But it does offer enough protection to slash the number of cases in infants for a time, a new study shows, and so Glaxo plans to ask European regulators for approval. The vaccine could be shipped by 2015. Report

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.